The Michael J. Fox Foundation (MJFF) introduced the Targets to Therapies (T2T) initiative, focusing on accelerating validation and tool development for 21 prioritized molecular targets in Parkinson’s disease. The open science model assembles expert cores dedicated to thorough target validation and toolkit creation, employing milestone-driven roadmaps with iterative decision points to enhance efficiency and resource allocation. This concentrated effort aims to derisk CNS drug development, stimulate collaboration, and ultimately expedite new disease-modifying therapies for this neurodegenerative disorder affecting millions globally.